Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (NCT01228318), a randomized phase 2 study. The primary outcome is Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels.

2. Clinical Question

The study rationale links immune changes associated with HIV/AIDS or highly active antiretroviral therapy (HAART) to bone turnover. In particular, the registry describes a proposed relationship involving RANKL and osteoprotegerin (OPG), which influence osteoclast activity and bone resorption. The clinical question assessed through CTx is therefore a question about a biochemical marker over time, rather than a direct measurement of bone mineral density or a clinical fracture outcome. The record does not report a single overall treatment contrast or a numerical result for the primary endpoint.

3. Trial Design

BLIR-HIV is a Phase 2, randomized, triple-masked, parallel-group study sponsored by Emory University. The registry records an enrollment of 63 and a completed status. The listed start is 2011-01, and primary completion is recorded as 2017-04-13. The record does not identify the randomization ratio, the method used to generate or conceal the allocation sequence, or the particular groups of people covered by triple masking.

The two arms are zoledronic acid and placebo. The intervention descriptions specify intravenous infusions administered over 15-30 minutes under study personnel supervision. The placebo description identifies mannitol and sodium citrate in a ready-to-infuse solution. The record does not report additional details such as treatment frequency, the timing of repeat administrations, or treatment adherence.

A parallel design assigns participants to an arm and compares outcomes between the arms over the study follow-up; it is distinct from a crossover design in which participants receive treatments in sequence. Randomization is intended, in general, to make the treatment groups comparable with respect to factors that could influence outcomes. Masking can reduce the influence of treatment knowledge on care, measurement, or assessment, depending on who is masked. These are general design principles, not further descriptions of procedures in this trial.

The primary outcome is baseline-adjusted mean CTx, assessed at baseline and scheduled visits from Week 12 through Week 144. The record says the adjusted means were estimated using analysis of covariance at each scheduled clinical visit. Participants with CTx measurements at the indicated week are included in the corresponding analysis. The listed secondary outcome is baseline-adjusted means of osteocalcin. Although the registry records five outcome measures, their full set of descriptions is not included in the available record. No protocol-level details on eligibility criteria, allocation procedures, masking roles, or the rationale for the enrollment target are reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Participants with CTx measurements at the indicated week are included in this analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels, measured over Baseline, Week 12 through Week 144.

The primary endpoint is the baseline-adjusted mean of serum C-terminal telopeptide of collagen (CTx), measured in ng/ml. CTx is described in the registry as an index of bone resorption. The stated assessment period is baseline, Week 12 through Week 144, with baseline-adjusted means estimated at each scheduled clinical visit.

Adjustment uses the baseline CTx value to account for starting levels when estimating follow-up responses. The registry defines the adjusted mean as the predicted response for each treatment arm at the mean baseline value for the two treatment arms. It states that analysis of covariance was used at each scheduled visit. The reported measure is therefore an adjusted group mean, not a raw change score or a participant-level result.

As a general statistical concept, baseline adjustment can improve the precision of a comparison when baseline measurements are related to follow-up values, and it can account for differences in starting measurements within the analysis. The registry record does not provide the model specification beyond the stated analysis of covariance, including any additional covariates or assumptions checked.

The biological rationale is that bone resorption is relevant to the concern about bone loss in people living with HIV/AIDS. The registry states that lower CTx values indicate better maintenance of bone mineral density. CTx remains a marker; the endpoint is not itself a direct measure of bone mineral density, fracture incidence, or long-term clinical benefit. Numerical adjusted means, confidence intervals, and between-arm results are not reported in the registry record, so the direction and precision of any observed comparison cannot be described from this record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a baseline-adjusted mean analysis of CTx at each scheduled clinical visit. It says that analysis of covariance was used and that the adjusted mean for each arm is the predicted response at the mean baseline value for the two treatment arms. This explains the form of the reported endpoint, but the numerical estimates and model details are not reported in the registry record.

What does baseline adjustment mean?

As a general statistical concept, adjustment uses a participant's baseline measurement as information in estimating follow-up outcomes. Rather than comparing follow-up values without regard to starting levels, a model estimates each arm's mean response at a common baseline value. In this trial's description, that common value is the mean baseline value for both arms. This can make the comparison more informative when baseline CTx is associated with later CTx.

An adjusted mean is a model-based estimate. Its interpretation depends on the model form and the data available to fit it. The registry states that analysis of covariance was used, but it does not report the covariates beyond baseline, how repeated measurements were handled across visits, diagnostic checks, or any transformations. Those details should not be inferred from the outcome title alone.

Why report a confidence interval?

The primary outcome description identifies a 95% confidence interval as the dispersion measure. In general, a confidence interval expresses the statistical uncertainty around an estimate under the model and sampling process. A narrower interval indicates greater precision than a wider interval, while the interval's position relative to a relevant comparison value helps assess what effects are compatible with the data. It is not a guarantee that the true value lies within the particular interval, nor does it describe the range of individual participant outcomes.

Although the endpoint description names a 95% confidence interval, the actual intervals and estimates are not reported in the registry record. No interpretation of their width or location is therefore possible. The record also does not provide a formal between-arm contrast, its confidence interval, or a test result for the primary outcome. Separate arm means alone, if available, would not by themselves provide the uncertainty for a between-arm difference.

How should repeated visits be understood?

The outcome timeframe runs from baseline through Week 144, with scheduled visits including Week 12 through Week 144. The registry says adjusted means were estimated at each scheduled visit. In general, repeated measurements can show how an outcome changes over time, but observations from the same participant are related rather than independent. A statistical method that analyzes the full repeated-measures structure needs to account for that relationship. The record does not say whether a joint repeated-measures model was used or whether each visit was analyzed separately beyond its statement that adjusted means were estimated at each visit.

Because the registry describes participant inclusion according to whether a CTx measurement is available at the indicated week, the number contributing may vary by visit. General interpretation of a visit-specific estimate should account for who remains measured at that visit and whether missingness could be related to treatment or outcome. Numbers analyzed by visit and missing-data methods are not reported in the registry record.

What do the planning assumptions mean?

The record describes planning illustrations based on the observed effect, using a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. It also says the effect to detect is a stated fraction of the observed effect. Such figures are planning scenarios, not observed trial findings and not evidence that the study had a particular probability of detecting an effect. A planning calculation illustrates the sample size associated with specified assumptions; it cannot replace the actual outcome estimate and its uncertainty.

The record does not report the trial's own sample-size justification, the assumed effect used when planning the trial, or any protocol-specific power calculation. The planning illustrations described in the record are distinct from that missing design rationale. They should not be read as observed power, which is not a useful substitute for interpreting an estimate and confidence interval.

General statistical interpretation also depends on the prespecified analysis plan: the outcome definition, visit selection, model, treatment contrast, handling of missing observations, and approach to multiple testing. The registry record does not report enough of those details to reconstruct the full analysis. It does state the endpoint, baseline adjustment, analysis of covariance, and visit-specific measurement population; those are the limits of the methodological description available.

10. Multiplicity, Missing Data and Analysis Populations

The primary CTx outcome is assessed at multiple scheduled visits, and the registry describes an adjusted mean at each visit. Examining multiple visits can raise a multiplicity question: if each visit is tested separately, the chance of at least one apparently unusual result may differ from the chance associated with a single prespecified test. As a general principle, a trial can address this by defining a primary visit, using an overall longitudinal test, or applying an adjustment strategy. The registry record does not report a multiplicity plan, a designated primary visit, or an overall treatment-by-time test.

The record lists baseline-adjusted means of osteocalcin as a secondary outcome and records five outcome measures in total. The full outcome set and the statistical analysis details for those outcomes are not reported in the registry record. It records zero analysis entries, so analysis-level results, including test statistics or treatment contrasts, are not reported in the registry record. This does not establish whether analyses were performed outside the registry; it describes what the registry record contains.

For the primary CTx outcome, the stated population at each indicated week consists of participants with a measurement at that week. The record does not report how many participants were analyzed at each visit, reasons for missing measurements, the amount or pattern of missingness, or any imputation or sensitivity analyses. In general, complete-case estimates can be affected if having a measurement is related to treatment assignment or the outcome. Whether that concern applies cannot be determined from the record.

The registry also does not report whether the analysis followed intention-to-treat principles, how deviations from assigned treatment were handled, or whether any per-protocol or other analysis populations were used. Without these details, the implications of missing measurements and analysis-population choices cannot be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: hospitalization due to community acquired pneumonia (10.3%), psychiatric hospitalization (3.4%), hospitalization related to graves' disease (3.4%), hospitalization due to sub-acute cerebrovascular accident (3.4%), hospitalization due to pancreatitis (2.9%).

The registry records serious adverse events for 34 participants at risk in the zoledronic acid group, with 7 affected, and 29 at risk in the placebo group, with 6 affected. For other adverse events, the corresponding at-risk and affected counts are 34 and 34 for zoledronic acid, and 29 and 28 for placebo. Deaths are recorded as 0 in each group. These are the registry's reported counts; the record does not provide a comparative statistical analysis of them.

The serious-event terms listed as the most common include hospitalization due to community acquired pneumonia (10.3%), psychiatric hospitalization (3.4%), hospitalization related to Graves' Disease (3.4%), hospitalization due to sub-acute cerebrovascular accident (3.4%), hospitalization due to pancreatitis (2.9%), and hospitalization due to abdominal pain (2.9%). The registry does not provide enough detail alongside these terms to determine whether categories overlap, how each percentage was calculated, or whether events were considered related to assigned treatment.

In general, adverse-event counts need context: definitions, ascertainment, follow-up duration, severity, relatedness, and the number of participants observed. Those details are not reported in the registry record. Counts should not be treated as proof of causation or as a complete comparison of safety between groups. The record also does not describe event timing, recurrent events, or withdrawals attributed to adverse events.

12. What the Result Does, and Does Not, Mean

The trial addresses a biologically motivated question: whether zoledronic acid compared with placebo is associated with differences in a bone-resorption marker among people with HIV infection. Its primary measure is baseline-adjusted serum CTx, assessed at scheduled visits from baseline through Week 144. The registry's rationale connects HIV/AIDS, HAART, immune reconstitution, RANKL, OPG, and bone resorption, while the endpoint measures CTx rather than those proposed immune mechanisms directly.

The record does not report numerical CTx results, between-arm estimates, confidence intervals, or statistical tests. It therefore cannot establish the direction, size, or precision of a treatment comparison. It also cannot establish whether any difference persisted, changed over time, or was clinically meaningful. The listed endpoint description says lower CTx values indicate better maintenance of bone mineral density, but numerical results are necessary to apply that interpretation to the trial.

A marker result, even when reported, would not by itself answer every question about bone health. CTx is not a direct measurement of bone mineral density and is not a fracture outcome. The registry lists bone loss, osteopenia, and osteoporosis among the conditions, but does not report primary results for those conditions in the record. The trial's stated endpoint should not be taken as evidence about clinical outcomes that are not reported.

The record's completion status and enrollment count describe the study, not its outcome. Safety counts offer some event information, but without fuller definitions and comparative analysis they do not establish causality or a comprehensive treatment-risk profile. Likewise, a plausible biological rationale is not evidence that the proposed mechanism was confirmed.

Accordingly, the defensible interpretation is limited to the registered design, endpoint definition, analysis description, and recorded safety counts. Efficacy, precision, clinical importance, and the proposed mechanism remain unassessable from the numerical results in the registry record because those results are not reported there.

13. Why This Trial Matters Statistically

This trial is statistically notable for combining randomized treatment assignment with a continuous biomarker measured repeatedly over an extended scheduled follow-up. Its design raises practical issues that occur in many clinical studies: adjustment for baseline values, interpretation of estimates at multiple visits, and analysis populations that may change when measurements are missing. These issues matter even when the outcome is a laboratory marker rather than a direct clinical event.

Baseline-adjusted means can be useful because starting values may be associated with later measurements. But the interpretation depends on the model and on how the analysis handles repeated observations, missing values, and multiple visits. The registry reports analysis of covariance at each scheduled visit, yet does not give enough detail to determine whether estimates were combined across time or how multiplicity was handled. The absence of numerical estimates also prevents readers from judging precision or separating a small, uncertain difference from a larger, more precisely estimated one.

The registry's stated rationale offers an example of the distinction between a mechanism and an endpoint. RANKL, OPG, immune reconstitution, and bone resorption motivate the research question; the primary endpoint is CTx. An outcome can be biologically relevant without directly measuring every link in the proposed pathway. Conclusions about the mechanism require appropriate mechanistic measurements and results, which are not reported in the registry record.

Finally, the record illustrates why completed status is not equivalent to an interpretable results report. A clear account of estimates, confidence intervals, analysis populations, and missing-data handling is necessary for statistical interpretation. The available record specifies important design and endpoint features but leaves those result-level elements unreported, limiting what can be concluded about the primary comparison.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting this trial from its registry record is that numerical primary outcome results are not reported. The record names baseline-adjusted CTx means and a 95% confidence interval as the dispersion measure, but does not give the estimates, intervals, or an explicit between-arm contrast. As a result, neither effect direction nor precision can be assessed.

The endpoint is measured at multiple scheduled visits, yet the record does not report a primary visit, an overall longitudinal estimate, or a multiplicity strategy. It says analysis of covariance was used at each visit but does not specify the full model, additional covariates, repeated-measures handling, or model diagnostics. These omissions prevent independent appraisal of the analysis approach.

The primary population is described as participants with CTx measurements at the indicated week. Visit-specific sample sizes, missing-data patterns, reasons for missingness, and methods for handling missing observations are not reported in the registry record. The record also does not say whether the primary analysis followed an intention-to-treat approach or describe any alternative analysis populations.

Other design details are also absent, including eligibility criteria, allocation sequence and concealment procedures, the roles covered by triple masking, treatment frequency, and the rationale for the enrollment target. The registry lists a secondary osteocalcin outcome and five outcome measures in total, but the complete outcome descriptions and analysis details are not available in this record. Safety counts are recorded, but fuller information on event definitions, timing, severity, relatedness, and analysis is not reported.

These limitations concern what can be interpreted from the registry record and do not establish that procedures or analyses were absent from the full study. They do mean that the recorded information is insufficient for a complete statistical assessment of treatment effects, missing data, or safety comparisons.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) — NCT01228318.
• Registry record last updated 2018-06-26; status last verified 2018-05.
• Results first posted 2018-06-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

BLIR-HIV (NCT01228318) is a completed Phase 2, randomized, triple-masked, parallel-group trial sponsored by Emory University, with enrollment recorded as 63. The study compares zoledronic acid with placebo in people with HIV infection. Its primary endpoint is baseline-adjusted serum CTx, assessed at scheduled visits from baseline through Week 144. The registry describes analysis of covariance at each visit and includes participants with a CTx measurement at the indicated week.

The record lists baseline-adjusted means of osteocalcin as a secondary outcome and records serious and other adverse-event counts, including 0 deaths in each group. It does not report numerical primary endpoint results, confidence intervals, formal treatment comparisons, or sufficient detail on multiplicity and missing-data handling. The result-level interpretation is therefore limited to what the registry record explicitly reports.